149 related articles for article (PubMed ID: 22071989)
1. Rapamycin inhibits osteoclast formation in giant cell tumor of bone through the C/EBPβ - MafB axis.
Smink JJ; Tunn PU; Leutz A
J Mol Med (Berl); 2012 Jan; 90(1):25-30. PubMed ID: 22071989
[TBL] [Abstract][Full Text] [Related]
2. Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB.
Smink JJ; Bégay V; Schoenmaker T; Sterneck E; de Vries TJ; Leutz A
EMBO J; 2009 Jun; 28(12):1769-81. PubMed ID: 19440205
[TBL] [Abstract][Full Text] [Related]
3. CCAAT/enhancer binding protein beta is up-regulated in giant cell tumor of bone and regulates RANKL expression.
Ng PK; Tsui SK; Lau CP; Wong CH; Wong WH; Huang L; Kumta SM
J Cell Biochem; 2010 May; 110(2):438-46. PubMed ID: 20225273
[TBL] [Abstract][Full Text] [Related]
4. Rapamycin and the transcription factor C/EBPbeta as a switch in osteoclast differentiation: implications for lytic bone diseases.
Smink JJ; Leutz A
J Mol Med (Berl); 2010 Mar; 88(3):227-33. PubMed ID: 19943027
[TBL] [Abstract][Full Text] [Related]
5. Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.
Huang L; Xu J; Wood DJ; Zheng MH
Am J Pathol; 2000 Mar; 156(3):761-7. PubMed ID: 10702390
[TBL] [Abstract][Full Text] [Related]
6. CCAAT/enhancer-binding protein β promotes receptor activator of nuclear factor-kappa-B ligand (RANKL) expression and osteoclast formation in the synovium in rheumatoid arthritis.
Tsushima H; Okazaki K; Ishihara K; Ushijima T; Iwamoto Y
Arthritis Res Ther; 2015 Feb; 17(1):31. PubMed ID: 25811130
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib Inhibits Giant Cell Tumor of Bone through Induction of Cell Apoptosis and Inhibition of Osteoclast Recruitment, Giant Cell Formation, and Bone Resorption.
Xu L; Luo J; Jin R; Yue Z; Sun P; Yang Z; Yang X; Wan W; Zhang J; Li S; Liu M; Xiao J
Mol Cancer Ther; 2016 May; 15(5):854-65. PubMed ID: 26861247
[TBL] [Abstract][Full Text] [Related]
8. Expression and function of CCAAT/enhancer binding proteinbeta (C/EBPbeta) LAP and LIP isoforms in mouse mammary gland, tumors and cultured mammary epithelial cells.
Dearth LR; Hutt J; Sattler A; Gigliotti A; DeWille J
J Cell Biochem; 2001; 82(3):357-70. PubMed ID: 11500913
[TBL] [Abstract][Full Text] [Related]
9. EZH2 Supports Osteoclast Differentiation and Bone Resorption Via Epigenetic and Cytoplasmic Targets.
Adamik J; Pulugulla SH; Zhang P; Sun Q; Lontos K; Macar DA; Auron PE; Galson DL
J Bone Miner Res; 2020 Jan; 35(1):181-195. PubMed ID: 31487061
[TBL] [Abstract][Full Text] [Related]
10. Cytokines expressed in multinucleated cells: Paget's disease and giant cell tumors versus normal bone.
Mills BG; Frausto A
Calcif Tissue Int; 1997 Jul; 61(1):16-21. PubMed ID: 9192505
[TBL] [Abstract][Full Text] [Related]
11. CCAAT/enhancer binding protein β-deficiency enhances type 1 diabetic bone phenotype by increasing marrow adiposity and bone resorption.
Motyl KJ; Raetz M; Tekalur SA; Schwartz RC; McCabe LR
Am J Physiol Regul Integr Comp Physiol; 2011 May; 300(5):R1250-60. PubMed ID: 21346244
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-16-5p Inhibits Osteoclastogenesis in Giant Cell Tumor of Bone.
Sang S; Zhang Z; Qin S; Li C; Dong Y
Biomed Res Int; 2017; 2017():3173547. PubMed ID: 28589137
[TBL] [Abstract][Full Text] [Related]
13. TGF-β induced PAR-1 expression promotes tumor progression and osteoclast differentiation in giant cell tumor of bone.
Wang T; Jiao J; Zhang H; Zhou W; Li Z; Han S; Wang J; Yang X; Huang Q; Wu Z; Yan W; Xiao J
Int J Cancer; 2017 Oct; 141(8):1630-1642. PubMed ID: 28670703
[TBL] [Abstract][Full Text] [Related]
14. Deregulation of the endogenous C/EBPβ LIP isoform predisposes to tumorigenesis.
Bégay V; Smink JJ; Loddenkemper C; Zimmermann K; Rudolph C; Scheller M; Steinemann D; Leser U; Schlegelberger B; Stein H; Leutz A
J Mol Med (Berl); 2015 Jan; 93(1):39-49. PubMed ID: 25401168
[TBL] [Abstract][Full Text] [Related]
15. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
16. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
Si AI; Huang L; Xu J; Kumta SM; Wood D; Zheng MH
J Cell Biochem; 2003 Aug; 89(6):1154-63. PubMed ID: 12898514
[TBL] [Abstract][Full Text] [Related]
17. Characterization of MicroRNA Expression Profiles in Patients with Giant Cell Tumor.
Qin S; He NB; Yan HL; Dong Y
Orthop Surg; 2016 May; 8(2):212-9. PubMed ID: 27384730
[TBL] [Abstract][Full Text] [Related]
18. Regulation of adipocyte 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) by CCAAT/enhancer-binding protein (C/EBP) β isoforms, LIP and LAP.
Esteves CL; Kelly V; Bégay V; Man TY; Morton NM; Leutz A; Seckl JR; Chapman KE
PLoS One; 2012; 7(5):e37953. PubMed ID: 22662254
[TBL] [Abstract][Full Text] [Related]
19. PPAR agonists modulate human osteoclast formation and activity in vitro.
Chan BY; Gartland A; Wilson PJ; Buckley KA; Dillon JP; Fraser WD; Gallagher JA
Bone; 2007 Jan; 40(1):149-59. PubMed ID: 17010686
[TBL] [Abstract][Full Text] [Related]
20. Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone.
Atkins GJ; Bouralexis S; Haynes DR; Graves SE; Geary SM; Evdokiou A; Zannettino AC; Hay S; Findlay DM
Bone; 2001 Apr; 28(4):370-7. PubMed ID: 11336917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
